| Zyflamend — is a proprietary, oral, multi-herbal botanical formulation manufactured by New Chapter, containing concentrated extracts of ten plants: rosemary, turmeric, ginger, holy basil, green tea, Hu Zhang (Polygonum cuspidatum), Chinese goldthread, barberry, oregano, and Baikal skullcap. Classified as a multi-component botanical protocol and dietary supplement, Zyflamend (ZYF) combines anti-inflammatory and polyphenolic phytochemicals including curcuminoids, catechins, carnosic acid derivatives, berberine-related alkaloids, resveratrol-related constituents, and baicalin-related flavonoids. Its anticancer activity has been investigated primarily in prostate cancer models, including castration-resistant prostate cancer, with additional studies in melanoma and pancreatic neuroendocrine tumor cells. It is not an approved cancer therapy.
Zyflamend – Ingredients and Quantities
Serving size: 2 capsules daily.
Total botanical extracts: 780 mg.
| Rank |
Ingredient |
Botanical Name |
Quantity |
Extract Type |
Major Bioactive Compounds |
| 1 |
Rosemary |
Salvia rosmarinus |
150 mg |
100 mg supercritical + 50 mg hydroethanolic |
Carnosic acid,
carnosol,
rosmarinic acid
|
| 2 |
Turmeric |
Curcuma longa |
110 mg |
100 mg aqueous + 10 mg supercritical |
Curcumin,
turmerones
|
| 3 |
Ginger
|
Zingiber officinale |
100 mg |
54 mg supercritical + 46 mg aqueous |
Gingerols, shogaols,
zingiberene
|
| 4 |
Holy Basil (Tulsi)
|
Ocimum tenuiflorum |
100 mg |
Hydroethanolic |
Ursolic acid,
eugenol,
rosmarinic acid
|
| 5 |
Green Tea |
Camellia sinensis |
100 mg |
Aqueous |
EGCG,
catechins,
polyphenols
|
| 6 |
Hu Zhang |
Reynoutria japonica (Polygonum cuspidatum) |
80 mg |
Hydroethanolic |
Resveratrol,
polydatin,
emodin
|
| 7 |
Chinese Goldthread |
Coptis chinensis |
40 mg |
Aqueous |
Berberine,
coptisine,
palmatine
|
| 8 |
Barberry |
Berberis vulgaris |
40 mg |
Hydroethanolic |
Berberine,
berbamine
|
| 9 |
Oregano
|
Origanum vulgare |
40 mg |
Supercritical |
Carvacrol,
thymol
|
| 10 |
Chinese Skullcap |
Scutellaria baicalensis |
20 mg |
Aqueous |
Baicalin,
baicalein,
wogonin
|
| Total Botanical Extracts |
780 mg |
Per 2 capsules |
Other ingredients:
Extra-virgin olive oil,
hypromellose capsule, candelilla wax and
organic yellow beeswax. Quantities not disclosed.
Notes: Botanical extract quantities are
not equivalent to purified active-compound quantities.
The concentrations of curcumin, EGCG, resveratrol,
berberine and other individual phytochemicals
are not specified. Values reflect the previously
listed formulation and should be checked against
the product label for the specific batch.
Primary mechanisms (ranked):
- Androgen receptor signaling inhibition: ↓ AR expression and transcriptional activity, with ↓ PSA and attenuation of IGF-1R/AKT-associated survival signaling in prostate cancer models.
- Epigenetic regulation: ↓ class I and II histone deacetylases (HDACs), ↑ CBP/p300 and histone H3 acetylation, and ↑ p21/CDKN1A expression, promoting cell-cycle arrest.
- Inflammatory pathway suppression: ↓ COX-1 and COX-2 enzymatic activity, with context-dependent ↓ NF-κB signaling and inflammatory mediators.
- Apoptosis induction: ↑ caspase-3 activation and PARP cleavage, contributing to decreased tumor cell survival.
- Cell-cycle regulation: ↑ p21 and p27, reduced proliferation and context-dependent cell-cycle arrest.
- ER stress and autophagy signaling: ↑ PERK, IRE1α, eIF2α, CHOP and JNK activation, promoting autophagy-associated apoptosis in pancreatic neuroendocrine tumor models.
- Growth and survival signaling suppression: ↓ phosphorylated AKT, STAT3 and PKC in selected prostate cancer models.
- Hormonal therapy sensitization: enhanced bicalutamide-associated growth inhibition in vitro and enhanced androgen-deprivation effects in prostate cancer xenografts.
Bioavailability / PK relevance: Zyflamend is administered orally as an oil-based mixture of botanical extracts. Its constituents have markedly different absorption, metabolism, conjugation, tissue distribution and elimination characteristics. Some polyphenols undergo extensive intestinal and hepatic first-pass metabolism. No validated integrated human plasma concentration profile or pharmacokinetic exposure-response relationship exists for the complete formulation. The manufacturer recommends two capsules daily with food; this is a supplement dose, not an established anticancer dose.
In-vitro vs systemic exposure relevance: Many mechanistic studies used approximately 200 µg/mL of complete Zyflamend preparation, often over 24–96 hours. Whether equivalent concentrations of the intact formulation or relevant active constituents can be achieved in human tumor tissue is unknown and has not been demonstrated. Oral absorption produces individual metabolites rather than a circulating mixture identical to the culture preparation. Consequently, direct translation of these in-vitro effects to standard oral dosing is not established.
Clinical evidence status: Preclinical: multiple prostate cancer cell studies and animal xenograft experiments demonstrate antiproliferative effects. Small human: an uncontrolled Phase I study in 23 evaluable men with high-grade prostatic intraepithelial neoplasia investigated an intervention including Zyflamend and other supplements over 18 months, reporting generally mild adverse effects, reduced NF-κB staining, and PSA changes in some participants. RCT: no adequately powered randomized evidence establishes anticancer efficacy. Adjunct use: experimental only; not established as a replacement for or proven enhancement of conventional cancer therapy.
Safety / limitations: Reported clinical adverse effects were mainly mild gastrointestinal symptoms. Potential concerns include herb-drug interactions, effects on platelet function, altered drug-metabolizing enzymes and transporters, and rare hepatic adverse effects associated with certain concentrated botanical extracts. Caution is warranted with anticoagulants, antiplatelet medications, anticancer drugs, liver disease, and perioperative use. In-vitro inhibition of nonmalignant prostate epithelial cell proliferation indicates that tumor selectivity cannot be assumed.
Zyflamend: Cancer Mechanisms
| Rank |
Pathway / Axis |
Cancer Cells |
Normal Cells |
TSF |
Primary Effect |
Notes / Interpretation |
| 1 |
Androgen Receptor / PSA |
↓ AR expression and activity; ↓ PSA |
Not established |
G |
Reduced androgen-dependent tumor signaling |
Core mechanism in prostate cancer, including castration-resistant models. May affect AR expression and associated survival signaling. |
| 2 |
HDAC1–7 / Histone H3 Acetylation |
↓ HDAC expression and activity; ↑ histone H3 acetylation |
Not fully characterized |
G |
Epigenetic suppression of proliferation |
Strong mechanistic evidence in CWR22Rv1 cells. Goldthread and Baikal skullcap contributed substantially to HDAC modulation. |
| 3 |
p21 / p27 / Cell Cycle |
↑ p21; ↑ p27; ↓ proliferation |
↓ proliferation observed |
G |
Cell-cycle arrest and growth suppression |
p21 knockdown partially reverses growth inhibition, supporting a functional role. Effects are not exclusive to cancer cells. |
| 4 |
COX-1 / COX-2 / Prostaglandins |
↓ COX enzymatic activity |
↓ COX activity possible |
P–G |
Anti-inflammatory signaling |
Direct COX inhibition demonstrated. Cancer-cell apoptosis can occur independently of COX-2 expression. |
| 5 |
NF-κB / Inflammatory Signaling |
↓ NF-κB (context-dependent) |
Not established |
G |
Reduced inflammatory and survival signaling |
Reduced tissue NF-κB immunostaining reported in the small HGPIN clinical study; clinical consequences remain uncertain. |
| 6 |
Caspase-3 / PARP / Apoptosis |
↑ caspase-3; ↑ PARP cleavage; ↑ apoptosis |
Selectivity uncertain |
G |
Programmed tumor-cell death |
Observed in prostate cancer models. Apoptotic induction is cell-type and concentration-dependent. |
| 7 |
IGF-1R / PI3K / AKT |
↓ pAKT and associated survival signaling |
Not established |
G |
Reduced proliferative and castration-resistant signaling |
Supported by prostate cancer models and tumor xenograft biomarker measurements. |
| 8 |
STAT3 / PKC |
↓ pSTAT3; ↓ activated PKC |
Not established |
G |
Suppression of oncogenic signaling |
Observed in LNCaP prostate cancer cells; broader relevance remains model-dependent. |
| 9 |
ER Stress / PERK / IRE1α / CHOP |
↑ ER stress and CHOP signaling |
Not established |
G |
Stress-mediated apoptosis |
Demonstrated primarily in pancreatic β-TC6 insulinoma cells at high experimental concentrations. |
| 10 |
JNK / Autophagy / Apoptosis |
↑ JNK; ↑ autophagy-associated apoptosis |
Not established |
G |
Stress-induced tumor-cell death |
JNK inhibition reduced apoptosis in pancreatic neuroendocrine tumor cells. Autophagy effects vary by cancer model. |
| 11 |
ERK1/2 / CBP-p300 |
↑ pERK; ↑ CBP/p300 acetylation |
Not established |
G |
p21 transcriptional regulation |
ERK activation supports p21 induction in CWR22Rv1 cells; represents a context-dependent growth-inhibitory response. |
| 12 |
Hormonal Therapy Sensitization |
↑ response to bicalutamide and androgen deprivation |
Not established |
G |
Potential endocrine therapy adjunct |
In-vitro combination studies and mouse xenografts suggest benefit; no clinical efficacy established. |
| 13 |
Chemosensitization |
↑ stress-associated apoptosis with selected agents |
Not established |
G |
Experimental combination activity |
Effects with doxorubicin and streptozotocin were investigated in pancreatic cell models. Human benefit is unproven. |
| 14 |
ROS / Oxidative Stress |
↔ (context-dependent) |
↔ (context-dependent) |
R–G |
Secondary redox modulation |
Contains antioxidant phytochemicals, but a consistent ROS-directed anticancer mechanism has not been established for the complete preparation. |
| 15 |
Clinical Translation Constraint |
Effective tissue exposure unverified |
Normal-cell growth effects observed in vitro |
G |
Uncertain clinical anticancer efficacy |
Mixed-extract PK remains undefined. Many experiments use 200 µg/mL preparation. Small uncontrolled human study, formulation complexity and uncertain drug interactions limit extrapolation. |
TSF: P: 0–30 min R: 30 min–3 hr G: >3 hr
|